TelMDCare Is Providing Patients With Affordable Consultations and Treatments for Various Infections.

Lemont, IL, USA, 3rd December 2024, ZEX PR WIRETelMDCare has been a pioneer in providing telemedicine services to people across the nation. Their recent announcement to make treatment cheaper for a wider audience who need affordable care for common infections is a welcome development. The company aims to provide accessible healthcare for all individuals who have problematic common infections.

While common infections typically aren’t life threatening, they can lead to severe damage if left untreated. Such infections include vaginal yeast infections, urinary tract infections, or respiratory infections, while others are comparatively less risky, like sinusitis or ear infections. In both cases, swift professional assistance is needed. Recognizing the needs of patients, TelMDCare has come up with a cost-effective solution to ensure that everyone gets the help they require.

At TelMDCare, we understand the reservation of people in accessing medical healthcare due to surging costs,” a spokesperson for TelMDCare admitted. “Our enhanced telemedicine services provide patients with a swift and affordable consultation session to help identify common infections and prevent their spread to avoid any potential long-term harm. With this expansion, we aim to offer inexpensive solutions to all, especially when they need it most.”

Through TelMDCare’s inclusive platform, patients can schedule virtual appointments and get consultations from the comfort of their homes, via laptops or cell phones. TelMDCare’s network of healthcare professionals conduct audio or video calls to highlight, identify, diagnose, and inform you about the various ways to treat common infections, along with writing you a prescription without requiring in-person visits. This saves time and costs compared to conventional, face-to-face visits.

By broadening their services and introducing affordable solutions, TelMDCare is setting a standard for affordable and convenient healthcare access for needy patients. This new pricing initiative marks a huge advancement that aims to target patients who typically avoid or are unable to get help due to the high cost of traditional treatment options. Their system also helps prevent any delay in receiving urgent medical attention for serious infections, before they escalate into irreversible, dangerous conditions.

To learn more about TelMDCare’s services, please reach out to them at the contact information provided below.

About TelMDCare

TelMDCare is a pioneer in telemedicine services, providing cost-effective and convenient healthcare to people all across the United States. They leverage technology to provide patients with the help they need, regardless of their location. Prioritizing patient’s health, TelMDCare breaks the barrier in pursuing modern ways of treatment, for common infections, in a timely and affordable manner.

Contact Information:

Toll-Free Number: +1-800-230-2050
Address: JME Medical Service, P.O. BOX 577, 42 Stephen St, Lemont, IL 60439

TelMDCare’s Expansion in Telemedicine Services Provide Accessible Virtual Care for Chronic Conditions

Lemont, IL, USA, 3rd December 2024, ZEX PR WIRETelMDCare, a leading provider of virtual healthcare services, continues to stand out in the telemedicine industry with its wide range of treatment options. The company’s latest initiative focuses on expanding its telemedicine offerings for patients with chronic conditions, ensuring accessible and convenient personalized care around the nation for chronic patients.

Chronic conditions can have serious long-term health risks if left untreated. Due to tight schedules or long commutes, people tend to avoid getting treatments from healthcare facilities that are located at a long distance, which increases the risk of exacerbating a chronic condition. TelMDCare is addressing these barriers with its enhanced telemedicine platform, offering effective chronic treatment services through online consultations with licensed professionals.

At TelMDCare, we recognize the importance of receiving prompt and secure medical care for chronic issues,” said a spokesperson for TelMDCare. “Our expanded telemedicine services are aimed at transforming the experience of receiving professional medical care by making it more flexible, affordable and convenient, eliminating the need for frequent in-person visits.

Through TelMDCare’s easy-to-use and secure platform, patients can schedule appointments with licensed chronic care professionals who are qualified to diagnose and treat a range of chronic conditions. These conditions include but are not limited to acid reflux, asthma, depression, anxiety, high cholesterol, migraine, and medication refills of some other conditions. Virtual consultations are conducted in the form of either a voice call or a video conference, depending on the patient’s preference and severity of the condition. The platform’s virtual consultations provide a safe space for individuals to discuss any concerns they might have regarding the medication or symptoms, while ongoing follow-up care ensures continuity and effectiveness of treatment.

Remote consultations allow the convenience of seeking immediate help when experiencing visible symptoms. This is particularly essential for patients with chronic conditions as there are increased risks of severe health issues if left untreated. Conditions such as asthma, depression, and acid reflux are easily treatable when detected early; however, these can cause serious implications if not treated timely.

Those interested in learning more about TelMDCare’s chronic care services can find additional information below.

About TelMDCare

TelMDCare is a pioneer in the telemedicine industry, dedicated to improving healthcare access and convenience. Utilizing cutting-edge technology, TelMDCare offers comprehensive health services directly to patients, regardless of location. With a focus on providing personalized, high-quality care, TelMDCare’s platform addresses a wide range of health needs, transforming the traditional experience of receiving healthcare and ensuring that all patients receive the support they deserve, regardless of their location or circumstances.

Contact Information:

Toll-Free Number: +1-800-230-2050
Address: JME Medical Service, P.O. BOX 577, 42 Stephen St, Lemont, IL 60439

New York, NY – Stripperfans (https://stripperfans.com/), a premier social media fan club platform, is changing the way creators and performers connect with their audiences by offering secure, exclusive, and entrepreneur-driven tools that empower individuals to build communities and generate sustainable income.

Founded in 2020 by entrepreneur Elie Bellune, Stripperfans has rapidly gained traction as a go-to platform for performers, influencers, artists, and creators worldwide. It aims to provide an inclusive space where individuals can share original content with their most loyal followers, leveraging creativity and ingenuity to generate wealth on their terms.

A Platform Built for Performers and Fans

Stripperfans is not just another social platform; it’s a purpose-built ecosystem designed to foster meaningful connections. Performers can interact directly with fans, offer exclusive content, and build thriving online communities. Key features of the platform include:

  1. Exclusive Content Sharing: Performers can upload unique content that fans can’t find anywhere else, creating a sense of exclusivity.
  2. VIP Rooms and Private Messaging: Paid private messaging options allow for direct and secure interaction between fans and performers.
  3. Best-in-Class Security: Advanced security measures ensure that all interactions are private and safe for both fans and performers.

For fans, Stripperfans offers direct access to their favorite performers, along with exclusive content and experiences that are tailored to their interests.

Driving Entrepreneurial Growth

The mission of Stripperfans is deeply rooted in entrepreneurship. Elie Bellune envisioned the platform as a digital talent pool where individuals could monetize their talents and passions, regardless of location.

“Our platform is about more than just connecting performers and fans,” says Bellune. “It’s about empowering individuals to take control of their financial futures. In today’s economy, it’s crucial to have opportunities that allow for flexibility and creativity. Stripperfans gives people the tools they need to create wealth on their terms.”

A Vision for Global Impact

While headquartered in the United States, Stripperfans has its sights set on global expansion. The platform welcomes creators from all walks of life and every corner of the globe, emphasizing inclusivity and opportunity.

“We’re proud of our roots in America,” Bellune shares, “but our vision is truly global. Talent and creativity know no boundaries, and neither should the opportunities to monetize them. Whether explicit or not, your content is welcome here, and we aim to be a platform where everyone can thrive.”

Built for the Modern Creator

Stripperfans distinguishes itself with features that cater specifically to the needs of modern creators. In addition to its secure and private interaction tools, the platform fosters a community where performers can truly be themselves without fear of censorship or corporate interference.

“Our team is small but ambitious,” Bellune notes. “We’re driven by a desire to change the world through technology and talent. By offering a platform that celebrates individuality and creativity, we’re helping creators turn their passions into sustainable businesses.”

Looking to the Future

As Stripperfans continues to grow, the company remains committed to innovation and user empowerment. Plans are underway to introduce new tools and features that further enhance the performer-fan experience while ensuring the platform remains a safe and supportive space.

“The future belongs to those who never stop striving for change and growth,” Bellune concludes. “Stripperfans is here to help creators achieve their dreams and build the lives they’ve always wanted.”

For more information on how Stripperfans is revolutionizing the performer-fan relationship, visit https://stripperfans.com/.

About Stripperfans

Founded in 2020, Stripperfans is a premium social media fan club platform that enables creators, influencers, and performers to interact with their most loyal fans, share exclusive content, and build sustainable businesses. Headquartered in the United States, Stripperfans is committed to inclusivity, security, and supporting entrepreneurial growth worldwide.

Social Links

X: https://x.com/stripperfans

Instagram: https://www.instagram.com/stripperfans/

Media contact

Brand: Stripperfans

Cotact: Media team

Email: support@stripperfans.com

Website: https://stripperfans.com/

 

New York, United States, 3rd Dec 2024 – Keynode is a leading player in the world of cryptocurrencies, changing the way investors manage their digital assets. They offer the highest APY crypto staking opportunities, with Annual Percent Yields (APYs) as high as 17 percent.

This remarkable return is setting a new standard in the highly competitive stake market. Keynode empowers investors to grow their wealth efficiently while benefiting from an intuitive platform. For those aiming to maximize returns on their crypto investments, Keynode simplifies the process of earning impressive rewards with minimal effort.

A Game-Changer in Crypto Staking

In the competitive world of cryptocurrency, where trust and returns are necessities, Keynode rises as a symbol of honesty and profit potential. This platform has been carefully designed to streamline the staking process while maintaining exceptional security. By collaborating with regulated organizations, Keynode ensures user assets are well-protected, offering peace of mind to both novice and seasoned investors.

What truly sets Keynode apart is its user-first strategy. With daily payouts and entry-level staking plans starting at just $100, the platform removes traditional barriers, making crypto staking more accessible than ever to the worldwide audience.

Diverse Staking Options for Every Investor

Keynode facilitates staking for some major cryptocurrency coins, such as Ethereum (ETH), Solana (SOL), Polygon (MATIC), Cardano (ADA), Sui (SUI) and TRON (TRX).  Each coin has a unique staking duration, which gives investors great versatility.  Whether you are a long-term holder or looking for short-term gain, Keynode has a strategy that works for every case to achieve your goal.

The platform simplifies staking into three quick steps:

  1. Sign Up – A quick and easy registration process.
  2. Choose an Asset – Select from a wide variety of supported cryptocurrencies.
  3. Start Earning – Begin receiving daily rewards without the hassle of traditional investment strategies.

This user-friendly approach makes sure that even people who are new to cryptocurrency can participate confidently and make easy passive income.

Why Keynode Stands Out

Keynode not only offers the highest APYs crypto staking, but also simplifies the user experience. The platform features a user-friendly interface, 24/7 customer support, and a strong commitment to sincerity, earning the trust of investors worldwide in record time.

Keynode provides a highly secure and efficient crypto staking platform designed to protect user assets. Keynode partners with regulated corporations and advanced encryption technologies to safeguard user assets. 

Plus, Keynode’s diverse staking options empower investors to spread their investments across multiple cryptocurrencies, reducing risk while maximizing potential returns.

Access the Benefits of Daily Payouts

A standout feature of staking with Keynode is the promise of daily payouts. Unlike traditional financial systems, which often involve long lock-in periods and delayed interest refunds, Keynode allows users to maximize the benefits of their investments almost immediately.

This approach works well with the dynamic nature of the cryptocurrency market, where adaptability and liquidity are important. With Keynode, investors can control their assets and set staking durations and reward plans to meet their financial goals.

Driving Passive Income for a Digital Age

Crypto staking is shaping the way people generate passive income. Staking digital assets allows individuals to achieve steady returns without the need for constant trading or market speculation. Keynode provides a user-friendly, secure platform with competitive APYs that sets it apart from the competition.

Join the Revolution Today

Keynode is shaping a new era in cryptocurrency, making digital finance more stable, rewarding, and easily accessible to all. Whether you are a pro investor or taking your first steps into crypto, Keynode equips you with the equipment to maximize your digital asset ability.

Visit Keynode.net today to explore earning up to 17% APY and elevate your investment strategies to the next level. See why Keynode is the platform of choice for those looking to grow their wealth effortlessly through crypto staking.

Website: www.keynode.net

Phone: (+1) 678-310-6834

 

Media Contact

Organization: KeyNode

Contact Person: Kiven Scott

Website: https://keynode.net/

Email: Send Email

Address: 1325 Avenue of the Americas, New City, NY, United States, New York

City: New York

Country: United States

Release Id: 03122420786

The post Keynode Offers Crypto Staking Platforms: Unlock the Highest APY Crypto Staking Opportunities Today! appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

Fort Worth, Texas, 3rd December 2024, ZEX PR WIRE, Jake Robinson, co-founder of North Texas Acquisitions Group (NTAG), has been highlighted in an exclusive online interview, where he shares his journey and expertise in helping homeowners facing foreclosure. As a seasoned real estate professional, Robinson’s work is defined by his ability to create meaningful solutions for homeowners in distress, showing them that even the toughest situations can lead to new opportunities.

Founded in 2019 by Robinson and business partner Jake Gumbert, NTAG specializes in guiding homeowners through the complexities of foreclosure. Their mission is simple yet impactful: to help homeowners protect their equity, preserve their financial future, and regain control of their lives. In the interview, Robinson opens up about his motivations, his approach to problem-solving, and the critical role NTAG plays in the lives of their clients.

Robinson emphasizes the importance of empathy in his work, noting that many homeowners feel overwhelmed or ashamed when facing foreclosure. “When someone reaches out to us, they’re often in a place of fear and uncertainty,” he explains. “The first thing I tell them is, ‘You’re not alone, and we’re here to help.’” His focus on listening to each homeowner’s unique story and providing tailored solutions is a cornerstone of NTAG’s success.

One of the key takeaways from the interview is Robinson’s insistence that foreclosure is not inevitable. “There are so many tools and strategies available to prevent foreclosure,” he shares. “But homeowners need to act early. The sooner we’re brought into the process, the more options we have to create a positive outcome.”

Robinson also highlights the impact of technology in his work, explaining how advanced data analytics allows NTAG to identify at-risk homeowners early and streamline the foreclosure prevention process. However, he insists that technology is only part of the equation. “What I love most is how it complements the personal connection we build with homeowners,” he says. “Tools are helpful, but they’re only as good as the people using them.”

For Robinson, the most rewarding part of his work is seeing the relief on a homeowner’s face when they realize they have options. “It’s about giving people hope and showing them that even in tough times, there’s a way forward,” he explains.

Through NTAG, Jake Robinson continues to provide innovative solutions and compassionate guidance to homeowners in need, proving that with the right support, no challenge is insurmountable.

About Jake Robinson of NTAG

Jake Robinson is the co-founder of North Texas Acquisitions Group (NTAG), based in Fort Worth, Texas. Specializing in distressed properties and foreclosure prevention, Jake is dedicated to helping homeowners protect their equity and find solutions during challenging times. His innovative strategies and empathetic approach have made him a trusted resource for homeowners across Texas.

To read the full interview, click here.

Connecticut, US, 3rd December 2024, ZEX PR WIRE, As the end of the 2024 financial year approaches, now is the perfect time to reflect, plan, and prepare for future financial success. Shannon Csapilla, a finance professional based in Stamford, Connecticut, shares practical insights to help individuals make confident decisions about their financial goals and personal growth.

With a degree in Economics from the University of Rhode Island and years of experience in financial services, Shannon has built a career centered on helping others navigate complex challenges and create sustainable habits for long-term success.

“Financial planning isn’t just about numbers,” Shannon explains. “It’s about understanding what matters most to you and creating a plan to support that vision. Small, consistent steps can make a big difference.”

End-of-Year Habits to Build for Financial Success

Shannon emphasizes that preparation for the financial year-end doesn’t have to be overwhelming. Her advice focuses on simple, effective strategies:

  • Review and Adjust Your Goals: The end of the year is an ideal time to evaluate progress and realign your financial goals. “Take a moment to ask yourself if your current plan matches your priorities,” Shannon advises.

  • Stay Organized: Whether it’s managing receipts for tax season or tracking expenses, having a clear system reduces stress. “Use tools like apps or spreadsheets to stay on top of deadlines and details,” Shannon suggests.

  • Invest in Yourself: Lifelong learning and personal growth are essential. “Even outside of finances, learning new skills or exploring new interests keeps you adaptable,” she adds.

Balancing Challenges and Successes

Shannon acknowledges that building financial habits—and habits in general—isn’t always easy.

“Sometimes, time management is a challenge,” Shannon admits. “Balancing multiple responsibilities can feel overwhelming, but prioritizing and setting boundaries has helped me find balance.”

Despite these challenges, Shannon finds joy in the impact she makes. “The best part of my work is seeing someone feel more confident and secure in their plans,” she shares.

As 2024 draws to a close, Shannon encourages everyone to focus on progress over perfection.

“Reflect on what you’ve accomplished and where you want to go,” she says. “Even small changes, like setting up automatic savings or simplifying your budget, can have a big impact.”

For more insights and practical advice, Shannon encourages others to reach out through professional networks or local financial workshops.

About Shannon Csapilla
Shannon Csapilla is a finance professional based in Stamford, Connecticut, with a Bachelor’s Degree in Economics from the University of Rhode Island. She is passionate about helping others achieve financial stability and growth while promoting lifelong learning and mentoring young professionals.

Media Contact

Shannon Csapilla

https://www.shannoncsapilla.com/

https://www.linkedin.com/in/shannoncsap

Ontario, Canada, 3rd December 2024, ZEX PR WIRE, Larry Weltman, a seasoned expert in the commission advance sector, is the subject of a recent online interview.  With almost two decades of experience, Weltman shares insights into his innovative use of technology, client-focused approach, and the lessons that have guided his journey.

The feature delves into Weltman’s transition from South Africa to Canada, and how his accounting background prepared him to meet the unique challenges of his field. He discusses the critical role commission advances play in helping realtors manage cash flow during closing delays, noting that “providing tailored solutions has always been about simplifying agents’ lives so they can focus on their work.”

Weltman also emphasizes the importance of adapting to digital transformation, detailing how automated tools have streamlined commission advance services, enabling realtors across Canada to operate with greater efficiency and transparency. He reflects on the values that have shaped his career, such as teamwork, resilience, and relationship-building—qualities inspired by his love of soccer and his early professional experiences.

The interview highlights Weltman’s dedication to mentorship and his vision for the future of commission advances, including exploring AI and data-driven tools to better serve realtors. Readers can explore his perspectives on building client relationships, navigating market challenges, and embracing innovation by accessing the full interview here. This feature provides a compelling look at his impact on the commission advance industry and his unwavering support for real estate agents.

To read the full piece, visit the website here

SOFTECH TEXAS LLC announces plans to build the first NFC chip manufacturing factory in the U.S., marking a major milestone for domestic smart technology production. This initiative aims to reduce reliance on international suppliers, boost innovation, and strengthen the U.S. tech manufacturing landscape.

Houston, TX, 3rd December 2024, ZEX PR WIRESOFTECH TEXAS LLC, a trailblazer in NFC, GPS, and AR technologies, announces its plan to establish the first-ever NFC chip manufacturing factory in the United States. This ambitious project marks a significant milestone in the domestic production of NFC technology, positioning SOFTECH TEXAS LLC as a leader in the tech industry while driving innovation and economic growth.

With its roots in creating cutting-edge NFC-enabled products, SOFTECH TEXAS LLC aims to expand its impact by entering the manufacturing sector, ensuring greater control over production, quality, and innovation. This move will support the company’s commitment to delivering world-class NFC products while contributing to the advancement of the U.S. tech manufacturing ecosystem.

Innovative Brands Leading the Way

SOFTECH TEXAS LLC is already revolutionizing industries with its portfolio of eight smart brands, each showcasing the versatility and potential of NFC, GPS, and AR technologies:

  1. QOIKY (Smart Business Cards)

  2. CONIAX (Smart Magnets, Photos, and Canvases)

  3. KORBLE (Smart Greeting Cards)

  4. BORBLE (AR Coloring Cards)

  5. TAPY CAR (Smart Auto Dealer Signs)

  6. TAPPAX (Smart Luggage Tags)

  7. PETIOX (Smart Pet Tags)

  8. RINGOWE (Smart Love Rings)

Driving Innovation with Industry Leaders

Behind this bold venture are SOFTECH TEXAS LLC’s visionary leaders:

  • Ozkan Oz, Founder and inventor of globally recognized products such as CONIAX and KORBLE.

  • Ferhat Simsek, Co-Founder and owner of Lone Star Marble, a leader in the marble and pool industries.

  • Servet Ciltas, Co-Founder and owner of Corumar Marble, renowned for his extensive success in the U.S. market.

  • Selcuk Kaya, Strategic Partner for Softech Texas, will be Co-founder of the First NFC Factory and owner of KAYALAR MOTORS.

Together, they bring a unique blend of entrepreneurial vision, technological expertise, and business acumen to drive the company forward.

The Future of NFC Manufacturing in the U.S.

With the establishment of its NFC manufacturing facility, SOFTECH TEXAS LLC aims to:

  • Reduce reliance on international NFC chip suppliers.

  • Enhance product customization and innovation.

  • Create jobs and contribute to the U.S. economy.

About SOFTECH TEXAS LLC

SOFTECH TEXAS LLC is a pioneering technology company specializing in NFC, GPS, and AR applications. With plans to open the first NFC chip manufacturing factory in the United States, the company is poised to lead the future of smart technology. From groundbreaking products to cutting-edge manufacturing, SOFTECH TEXAS LLC is setting a new standard in innovation.

For more information, visit softechtexas.com.

IMG_256

In the financial markets, traders typically choose between FX brokers and prop firms, the two most popular trading platforms. Understanding their differences is essential for selecting the one that aligns with your trading goals.

Prop Firms vs. FX Brokers

1. Capital Support and Risk Control

On FX broker platforms like XM, Exness, and IG, traders must use their own funds. All trading risks are borne by the individual, meaning that traders with limited capital may face substantial risks.

In contrast, Prop Firms like Funding Pips, FTMO, and Funded Knight offer traders access to significant capital, allowing them to trade without risking their own money. For example, with Funded Knight, traders only need to pay around $1,000 for an evaluation and can trade with up to $250,000 in real trading capital (the evaluation fee is refundable). With such large capital backing, traders have the flexibility to implement more complex strategies, allowing them to fully unleash their trading potential. They can also set proper stop-loss and take-profit levels according to the size of the account, reducing the risk of premature exits caused by limited funds.

2. Trading Costs and Profit Sharing

Traditional FX brokers generate revenue through spreads, commissions, and fees without offering profit-sharing. This model leaves traders solely responsible for their success or failure, with high trading costs often reducing profitability.

On the other hand, Prop Firms often offer higher profit-sharing rates. For example, after passing the evaluation challenge with Funded Knight, traders can earn up to 95% of the profit, which is the highest percentage among Prop Firms. With the mission “Your success is our success,” Prop Firms share a mutual interest with traders, offering free, high-quality educational resources, training courses, and professional consulting to help traders succeed.

3. Entry Barriers to Trading

Traditional FX brokers focus on platform conditions and market access. Traders can start trading immediately by depositing funds, without the need to pass any evaluation. However, this model often leads to higher risk for traders, especially when capital is insufficient, making it difficult to weather market volatility.

Since Prop Firms fully bear the risk of any loss traders might incur, they usually set up evaluation stages and trading rules to assess traders’ skills and risk management abilities. While this may result in higher entry barriers compared to FX brokers, it is not difficult for traders to meet these requirements. For example, Funded Knight sets relatively low evaluation standards and offers a quicker, simpler “1-step challenge” that allows traders to access real trading faster than the typical two-phase evaluation process. The “1-step challenge” even has no time or minimum trading day limits, which encourages more potential traders to participate.

Additionally, Funded Knight has tailored its services to meet the needs of traders in Asia, particularly Southeast Asia. It provides multilingual support and integrates popular local payment gateways, ensuring a seamless trading experience for the region’s traders.

Summary

Returning to the original question: should individual traders choose Prop Firms or FX Brokers?

For traders with substantial capital and a preference for full control, traditional FX brokers may be suitable. However, if overcoming capital limitations and maximizing profitability are your priorities, prop firms like Funded Knight provide an ideal trading environment to achieve these goals.

Learn more: https://fundedknight.com

Company Name: FK FINTECH LIMITED

Contact Person: Funded Knight Support

Email: support@fundedknight.com

State: Hong Kong

Website: https://fundedknight.com

SHENZHEN, CHINAChina Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 2 December 2024, the Group through a wholly-owned subsidiary of the Company entered into an Exclusive Commercialization Agreement (the “Agreement”) with Atom Therapeutics Co., Ltd (hereinafter referred to as “Atom Therapeutics”, formerly named as “Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.”) of class 1 innovative drug ABP-671 for the treatment of gout and hyperuricemia (the “Product”). In accordance with the Agreement, the Group is entitled to an exclusive commercialization right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The term of cooperation commences on the effective date of the Agreement and extends for ten years from the date the Product is first approved for market launch in Mainland China (the “Authorization Term”). Upon the expiration of the Authorization Term, it may be automatically renewed for an additional ten years, subject to specific conditions stipulated in the Agreement.

 

ABP-671 is a class 1 innovative chemotherapeutic drug for the treatment of gout and hyperuricemia, currently in Phase 2b/3 clinical trials for gout in China and overseas. The Product reduces renal re-absorption of uric acid by inhibiting Urate Anion Transporter 1 (URAT1). The results of two completed phase 2 clinical trials demonstrated favorable efficacy and safety profiles across multiple dose groups (ranging from 1 mg to 12 mg) of ABP-671. The 2 mg once-daily dosage of the Product was proved to be as effective as, or even better than, benzbromarone or febuxostat (maximum dosage of 80mg). The reduction in uric acid levels was sustained throughout the 24-hour period, with no significant safety concerns identified. This product is anticipated to offer more effective and safer treatment alternatives for patients suffering from gout and hyperuricemia[1]. Multiple patents in regard to substance and use of the ABP-671 have been granted in China.

 

Hyperuricemia is defined as a fasting blood uric acid level exceeding 420μmol/L (7.0 mg/dL) in adults on a normal purine diet on two separate days. The deposition of urate crystals in hyperuricemia patient results in arthritis, medically termed gout. Hyperuricemia and gout can cause acute and chronic inflammatory injury in articular cartilage, bone, kidney and vascular wall, which can lead to multiple organ damage of the heart, brain and kidney, etc. The data presented in the White Paper on Hyperuric Acid and Gout Trends in China (2021) indicates that, the incidence rate of hyperuricemia is 13.3%, with approximately 177 million hyperuricemia patients and the incidence rate of gout is 1.1% in general, with about 14.66 million gout patients in China. Frost & Sullivan indicates that, the number of people with hyperuricemia and gout in China will continue to increase in the future, reaching 240 million and 52.2 million respectively by 2030. Currently, the commonly used uric acid-lowering drugs in clinical practice in China are those which inhibit uric acid synthesis or promote uric acid excretion. Due to certain limitations in the efficacy and safety of the marketed uric acid-lowering drugs, such as causing renal failure, sudden cardiac death or severe liver toxicity. There is still an urgent need for effective and safe uric acid-lowering drugs among gout and hyperuricemia patients in China.

 

ABP-671 is currently with the potential to be the promising and safe product for the treatment of gout and hyperuricemia. Through this collaboration, it fills the blank in the CMS’s product portfolio of the treatment of gout. Gout and hyperuricemia are both rheumatic diseases and chronic metabolic diseases, which are highly consistent with the Group’s strategic layout in the cardio-cerebrovascular/ gastroenterology business and the network resources of marketed products. If approved for marketing in the future, the Product will synergize with the Group’s marketed product Metoject (methotrexate injection) in rheumatology and with Elcitonin (elcatonin injection) in endocrinology and orthopedics, in terms of expert network and market resources. Based on the unmet clinical needs and the expected solid clinical data of the Product, the Group is looking forward to the smooth advancement of the clinical development of ABP-671, allowing patients with relevant indications to benefit from this innovative treatment sooner.

 

About ATOM THERAPEUTICS

Atom Therapeutics was founded in March 2012, focused on the research and development of innovative drugs with global commercial value and competitiveness in the metabolic and inflammatory area. Atom Therapeutics’s main core team members come from the United States, with extensive experience in the research and development of innovative drugs. Atom Therapeutics has achieved remarkable development in the past few years. Atom Therapeutics’s core product ABP-671 is under pivotal clinical stage for the treatment of chronic gout. Atom Therapeutics’s another small molecule innovative drug named as ABP-745, used for indications in the field of anti-inflammatory immune indications. The Phase 1 clinical of ABP-745 exhibited outstanding pharmacokinetics and safety. The clinical trial is on the verge of entering Phase 2. For more information about Atom Therapeutics and its pipeline, please visit https://www.atombp.com/.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.

 

Reference:

  1. The results of Phase 2 clinical trials was published and can be found at: https://www.atombp.com/2023/03/01/atom-bioscience-announces-positive-results-of-phase-2a-china-clinical-trial-of-its-urat1-inhibitor-for-chronic-gout/

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.